AssetMark’s Bicycle Therapeutics BCYC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,588
Closed -$6.73K – 3779
2026
Q2
$6.73K Sell
1,588
-2,630
-62% -$12.1K ﹤0.01% 2592
2026
Q1
$19.6K Buy
4,218
+590
+16% +$3.37K ﹤0.01% 2066
2025
Q4
$25.7K Buy
3,628
+3
+0.1% +$22 ﹤0.01% 1923
2025
Q3
$28.1K Buy
3,625
+1,552
+75% +$11.7K ﹤0.01% 1830
2025
Q2
$14.4K Buy
2,073
+791
+62% +$6.3K ﹤0.01% 1877
2025
Q1
$10.9K Buy
1,282
+22
+2% +$259 ﹤0.01% 1835
2024
Q4
$17.6K Sell
1,260
-259
-17% -$5.55K ﹤0.01% 1683
2024
Q3
$34.4K Buy
+1,519
New +$35K ﹤0.01% 1380

Other funds holding BCYC

AssetMark's BCYC Position: Q3 2026 in Review

AssetMark sold out of Bicycle Therapeutics (BCYC) in Q3 2026, closing a stake of 1,588 shares — an estimated $6.73K sold.

AssetMark first reported a position in BCYC in Q3 2024 and held it in 8 quarters. The position peaked at $34.4K in Q3 2024. 61 funds tracked by Wall St. Rank hold BCYC as of Q3 2026.

  • AssetMark reported no remaining Bicycle Therapeutics position as of Q3 2026 after selling out during the quarter.
  • AssetMark sold 1,588 Bicycle Therapeutics shares in Q3 2026, an estimated $6.73K.
  • AssetMark first reported a position in Bicycle Therapeutics in Q3 2024 and held it in 8 quarters.
  • AssetMark's Bicycle Therapeutics position peaked at $34.4K in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.